MedPath

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

Phase 3
Completed
Conditions
Dry Eye Syndromes
Registration Number
NCT00549289
Lead Sponsor
Sirion Therapeutics, Inc.
Brief Summary

The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Diagnosis of dry eye syndrome
Exclusion Criteria
  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the study
  • Pregnancy or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Clayton Eye Center

🇺🇸

Morrow, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath